Pfizer (PFE) Tops Q4 EPS by 7c; Guides FY 23 Below the Street

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. GOOGL
6. APGE
7. DFTX
8. MU
9. IBM
10. HOOD

Go back to Pfizer (PFE) Tops Q4 EPS by 7c; Guides FY 23 Below the Street

PFIZER REPORTS RECORD FULL-YEAR 2022 RESULTS AND PROVIDES FULL-YEAR 2023 FINANCIAL GUIDANCE

January 31, 2023 6:45 AM EST

Full-Year 2022 Revenues of $100.3 Billion, An All-Time High for Pfizer, Reflecting 30% Operational Growth Excluding Contributions from Paxlovid and Comirnaty(1), Revenues Grew 2% Operationally Strong Fourth-Quarter 2022 Revenues of $24.3 Billion, Reflecting 13% Operational Growth Excluding Contributions from Paxlovid and Comirnaty(1), Revenues Grew 5% Operationally Full-Year 2022 Reported Diluted EPS(2) of $5.47, Up 42% Year-Over-Year, and Adjusted Diluted EPS(3) of $6.58, Up 62% Year-Over-Year, Both of Which Represent All-Time Highs for Pfizer Fourth-Quarter 2022 Reported Diluted EPS(2) of $0.87, Up 48% Year-Over-Year, and Adjusted Diluted EPS(3) of $1.14, Up 45% Year-Over-Year Includes a $0.32 Benefit from Lower Acquired IPR&D Expenses... More